M 7583

Drug Profile

M 7583

Alternative Names: M7583

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EMD Serono
  • Developer EMD Serono; Merck KGaA
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B cell lymphoma

Most Recent Events

  • 09 Dec 2017 Efficacy and safety data from a phase I/II trial in B-cell lymphomas presented at the 59th Annual Meeting and Exposition of the American Society of Haematology (ASH-2017)
  • 04 Oct 2017 Merck plans a phase I trial in Healthy volunteers in Germany (NCT03297983)
  • 02 Jun 2017 Interim adverse events data from a phase I/II trial in B-cell lymphoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top